Sequel Med Tech and Senseonics announced full availability of the twiist automated insulin delivery (AID) system integrated with the Eversense 365 continuous glucose monitoring (CGM) system in the U.S.

Powered by Tidepool, twiist is touted as the first AID system compatible with Eversense 365, a one-year CGM. The combination can help reduce the burden of frequent sensor changes and re-pairing, with CGM accuracy.

“As the first AID system to integrate with a year‑long CGM, twiist expands the options available to people with diabetes,” said Joanna Mitri, MD, M.S., chief medical officer at Sequel. “People deserve choice and technology that fits the realities of their lives. Our goal is to provide a system that supports the many different ways individuals and care teams approach diabetes every day.”

Those using twiist can choose between two compatible CGM partners: Eversense 365 or Abbott’s FreeStyle Libre 3 Plus sensor, depending on their personal preferences and needs.

Eversense 365 is the only long-term CGM system available. It provides 365 days of uninterrupted glucose readings and the company said it’s the most accurate CGM in low glucose ranges where errors can have the most impact on patient safety and treatment decisions.

“National availability of Eversense 365 with twiist marks an important next phase of our journey,” said Brian Hansen, chief commercial officer of Senseonics. “It adds to the growing momentum behind Eversense 365, which is designed to provide reliable glucose data over longer periods of time in order to reduce the daily burden people with diabetes often face. By pairing this groundbreaking CGM with an advanced insulin delivery system, users can spend less time managing devices and more time focusing on their lives.”

Last week, Sequel began a collaboration to integrate Diabeloop’s DBLG2 algorithm into the twiist AID system.